Yahoo · Oct 7, 2026
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.
NV
NYSE · NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
$37.53
Up+$0.76 (+2.01%)
Updated Oct 7, 2026, 7:44 PM
SID Score
5.6/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 223.45B
- P/E ratio
- 12.76
- Dividend yield
- 4.48%
- 52-week range
- $35.12 – $64.16
- Volume
- 13.7M
- Avg. volume
- 16.69M
Price performance · NVO
NVO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NVO closed at $37.53 after 21 trading sessions, down 16.90% for the selected period.
- Last close
- $37.53
- Period change
- -16.90%
- Period low
- $37.32
- Period high
- $45.16
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $37.35 | $37.53 | $36.845 | $37.53 | 13.7M |
| Oct 5, 2026 | $36.94 | $37.61 | $36.855 | $37.54 | 18.7M |
| Oct 2, 2026 | $37.635 | $37.65 | $37.17 | $37.32 | 10.26M |
| Oct 1, 2026 | $37.80 | $37.97 | $37.365 | $37.40 | 12.66M |
| Sep 30, 2026 | $38.05 | $38.77 | $37.885 | $37.91 | 21.56M |
| Sep 29, 2026 | $38.21 | $38.38 | $38.05 | $38.31 | 9.4M |
| Sep 28, 2026 | $38.40 | $38.8984 | $38.2323 | $38.71 | 11.43M |
| Sep 25, 2026 | $38.81 | $38.83 | $38.41 | $38.80 | 10.06M |
| Sep 24, 2026 | $37.95 | $38.7197 | $37.92 | $38.62 | 20.06M |
| Sep 23, 2026 | $38.90 | $39.14 | $38.16 | $38.17 | 18.44M |
| Sep 22, 2026 | $39.50 | $39.89 | $39.105 | $39.40 | 24.46M |
| Sep 21, 2026 | $41.05 | $41.17 | $39.54 | $39.80 | 49.34M |
| Sep 18, 2026 | $43.50 | $43.54 | $42.78 | $43.24 | 10.37M |
| Sep 17, 2026 | $41.98 | $43.44 | $41.96 | $43.19 | 12.95M |
| Sep 16, 2026 | $42.47 | $42.72 | $41.47 | $41.71 | 11.67M |
| Sep 15, 2026 | $42.725 | $43.00 | $42.40 | $42.53 | 8.86M |
| Sep 14, 2026 | $43.66 | $43.71 | $43.0701 | $43.45 | 6.56M |
| Sep 11, 2026 | $43.195 | $43.4951 | $42.7216 | $43.07 | 11.03M |
| Sep 10, 2026 | $44.60 | $44.82 | $44.01 | $44.01 | 6.58M |
| Sep 9, 2026 | $45.00 | $45.395 | $44.52 | $44.56 | 8.83M |
| Sep 8, 2026 | $45.58 | $45.91 | $45.145 | $45.16 | 10.35M |
Latest NVO news
The latest Smart Investors Daily articles mentioning NVO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NVO research
Overview
Company profile and research snapshot.
Company profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Hold | — |
| Sep 22, 2026 | BANCO SANTANDER | Outperform | — |
| Sep 22, 2026 | DNB CARNEGIE | Buy | — |
| Sep 22, 2026 | TD COWEN | Hold | — |
News briefing
Generated Oct 7, 2026, 7:11 PM
Why Is NVO Up Today? Modest Gains Amid Strategic Crossroads
Novo Nordisk shares rose 1.85% today as the market digests a complex mix of headwinds and potential opportunities for the Danish pharmaceutical giant. While the stock remains down dramatically from its peak, recent news suggests investors are cautiously reconsidering the company's diversification strategy beyond its dominant GLP-1 franchise.
Bottom line: Novo Nordisk stands at an inflection point where steep valuation declines are being weighed against real competitive losses in GLP-1s and pipeline delays in promising alternatives. Investors should monitor diversification progress (particularly Denecimig and other non-GLP-1 assets) and whether the company can successfully transition beyond its challenged diabetes franchise before making significant commitments at these levels.
Yahoo · Oct 6, 2026
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Tuesday
Yahoo · Oct 6, 2026
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
Yahoo · Oct 6, 2026
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.
AI research layers
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares have experienced significant downward pressure across all measured timeframes, with the stock trading at $37.53 per SID market data. The stock has declined 20.99% over the past month and 24.38% over the trailing three-month period, reflecting substantial selling momentum. On a twelve-month basis, NVO has lost 36.09% of its value, marking one of the steeper drawdowns among large-cap healthcare names. Technical indicators confirm the bearish trend, with shares trading well below both the 50-day moving average of $44.45 and the 200-day moving average of $45.59, per Massive/Polygon data. The 14-day relative strength index sits at 24.4, placing the stock firmly in oversold territory. Despite the selloff, NVO maintains a market capitalization of approximately $223.5 billion. The stock's beta of 0.352 indicates historically low volatility relative to the broader market, making the recent decline particularly notable.
Novo Nordisk A/S Valuation Analysis
Following the sustained price decline, Novo Nordisk's valuation metrics have compressed meaningfully. The stock currently trades at a price-to-earnings ratio of 12.76, per SID market data, a level that appears modest for a large-cap healthcare company with dominant positioning in the GLP-1 receptor agonist market. The PEG ratio stands at 2.05, suggesting the current earnings multiple still carries a premium relative to the company's projected growth rate. Novo Nordisk's price-to-book ratio of 8.43, according to SEC filings, reflects the asset-light nature of its pharmaceutical business model and the intangible value embedded in its drug portfolio. The company offers a dividend yield of 3.66%, which has risen alongside the share price decline and now represents a meaningful income component for shareholders. Within the broader healthcare sector, Novo Nordisk's current P/E ratio positions it below many large-cap pharmaceutical peers, indicating a notable valuation reset from prior premium levels.
Smart Money Activity for NVO
Novo Nordisk's composite smart money score stands at 51 out of 100, generating a neutral signal according to SID market data. The institutional component registers the strongest reading at 23.0 out of 25, indicating robust ownership and sustained interest from large asset managers, per 13F institutional filings. Insider activity scores 12.5 out of 25, reflecting a moderate level of transactions by company executives and directors according to SEC Form 4 filings. Congressional trading activity scores 10.4 out of 25, suggesting limited but present interest from members of Congress and their disclosed portfolios. The dark pool activity component registers at only 5.0 out of 25, indicating relatively low levels of off-exchange block trading in recent periods. The divergence between strong institutional holdings and weak dark pool activity suggests that while major funds maintain their positions, there has been limited large-scale accumulation through alternative trading venues during the recent price decline. The overall neutral signal implies no clear directional conviction among sophisticated market participants at current price levels.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk faces a series of upcoming earnings reports that will be closely monitored by investors seeking clarity on the company's growth trajectory. According to analyst estimates compiled by SID, consensus expectations call for earnings of $0.81 per American Depositary Share across all four upcoming reporting periods. The next scheduled report date is August 21, 2026, followed by reports on August 25, August 28, and November 4, 2026. The uniform $0.81 estimate across quarters suggests analysts are projecting stable sequential earnings performance without significant variation. With the stock trading at $37.53 and a trailing P/E of 12.76, per company earnings reports, the implied forward earnings yield appears attractive relative to historical norms for the company. Actual results from these upcoming quarters will be critical in determining whether the recent 36.09% twelve-month decline reflects fundamental deterioration or a market overreaction that has created a valuation disconnect.
Wall Street Analyst Ratings for NVO
Recent Wall Street coverage of Novo Nordisk reflects a mixed but generally constructive stance, according to SID consensus data. On September 23, 2026, Rothschild & Co Redburn reiterated a Buy rating on NVO, while Jyske Bank maintained its Hold recommendation on the same date. On September 22, 2026, Banco Santander reiterated an Outperform rating, and DNB Carnegie maintained its Buy rating, per Wall Street analyst reports. TD Cowen also reiterated a Hold rating on September 22. Among these five most recent ratings, three reflect bullish positioning with Buy or Outperform designations, while two analysts maintain Hold ratings. Notably, none of the recent coverage actions involved downgrades, as all five analysts maintained their prior recommendations unchanged. The absence of any Sell ratings or negative rating changes among active coverage suggests that despite the stock's 36.09% twelve-month decline, the analyst community broadly views the selloff as not warranting a bearish thesis at current price levels around $37.53.
